Growth Metrics

NovoCure (NVCR) Receivables - Other (2022 - 2026)

NovoCure's Receivables - Other history spans 5 years, with the latest figure at $8.2 million for Q1 2026.

  • On a quarterly basis, Receivables - Other rose 25.64% to $8.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $8.2 million, a 25.64% increase, with the full-year FY2025 number at $7.8 million, up 36.02% from a year prior.
  • Receivables - Other hit $8.2 million in Q1 2026 for NovoCure, up from $7.8 million in the prior quarter.
  • Over the last five years, Receivables - Other for NVCR hit a ceiling of $8.2 million in Q1 2026 and a floor of $2.2 million in Q4 2022.
  • Historically, Receivables - Other has averaged $5.8 million across 5 years, with a median of $5.7 million in 2024.
  • Biggest five-year swings in Receivables - Other: surged 93.93% in 2023 and later rose 25.64% in 2026.
  • Tracing NVCR's Receivables - Other over 5 years: stood at $2.2 million in 2022, then soared by 93.93% to $4.3 million in 2023, then soared by 34.67% to $5.7 million in 2024, then surged by 36.02% to $7.8 million in 2025, then rose by 5.89% to $8.2 million in 2026.
  • Business Quant data shows Receivables - Other for NVCR at $8.2 million in Q1 2026, $7.8 million in Q4 2025, and $7.2 million in Q3 2025.